Europe Acute Myeloid Leukemia Diagnostics Market
Taille du marché en milliards USD
TCAC :
% 
 Période de prévision |
2023 –2030 |
 Taille du marché (année de référence) |
USD 702.84 Million |
 Taille du marché (année de prévision) |
USD 1,662.45 Million |
 TCAC |
% |
| Principaux acteurs du marché |
>Marché européen du diagnostic de la leucémie myéloïde aiguë, par type de produit (instruments et consommables et accessoires), type de test (test d'imagerie, test sanguin, tests de moelle osseuse , test de biomarqueurs, immunophénotypage, tests génétiques et autres), type de cancer (myéloblastique (M0), myéloblastique (M1), myéloblastique (M2), promyélocytaire (M3), myélomonocytaire (M4), monocytaire (M5), érythroleucémie (M6) et mégacaryocytaire (M7)), groupe d'âge (moins de 21 ans, 21-29, 30-65 ans et 65 ans et plus), sexe (homme et femme), utilisateur final (hôpital, laboratoires associés, laboratoires de diagnostic indépendants, centres d'imagerie diagnostique, instituts de recherche sur le cancer et autres), canal de distribution (appel d'offres direct et vente au détail) Tendances de l'industrie et prévisions jusqu'en 2030.
Analyse et perspectives du marché européen du diagnostic de la leucémie myéloïde aiguë
En raison de l'augmentation des dépenses de santé, la croissance du marché s'accélère, ce qui peut se traduire par de meilleures opportunités de recherche et développement. En outre, l'augmentation du nombre de laboratoires de recherche clinique et de diagnostic pour le diagnostic du cancer permet au marché de se développer.
Le marché européen du diagnostic de la leucémie myéloïde aiguë devrait croître au cours de la période de prévision de 2023 à 2030. Data Bridge Market Research analyse que le marché croît avec un TCAC de 11,4 % au cours de la période de prévision de 2023 à 2030 et devrait atteindre 1 662,45 millions USD d'ici 2030 contre 702,84 millions USD en 2022.
|
Rapport métrique |
Détails |
|
Période de prévision |
2023 à 2030 |
|
Année de base |
2022 |
|
Année historique |
2021 (personnalisable pour 2020-2016) |
|
Unités quantitatives |
Chiffre d'affaires en millions USD |
|
Segments couverts |
Par type de produit (instruments, consommables et accessoires), type de test (test d'imagerie, test sanguin, tests de moelle osseuse, test de biomarqueurs, immunophénotypage, tests génétiques et autres), type de cancer (myéloblastique (M0), myéloblastique (M1), myéloblastique (M2), promyélocytaire (M3), myélomonocytaire (M4), monocytaire (M5), érythroleucémie (M6) et mégacaryocytaire (M7)), groupe d'âge (moins de 21 ans, 21-29 ans, 30-65 ans et 65 ans et plus), sexe (homme et femme), utilisateur final (hôpital, laboratoires associés, laboratoires de diagnostic indépendants, centres d'imagerie diagnostique, instituts de recherche sur le cancer et autres), canal de distribution (appel d'offres direct et vente au détail). |
|
Pays couverts |
Allemagne, Royaume-Uni, France, Italie, Espagne, Russie, Pays-Bas, Suisse, Belgique, Turquie et reste de l'Europe. |
|
Acteurs du marché couverts |
Epigenomics AG, F. Hoffmann-La Roche Ltd, Siemens Healthcare GmbH, BIOMERIEUX, Merck KGaA, DiaSorin SpA, Koninklijke Philips NV, Sonic Healthcare et SternMed GmbH, entre autres. |
Définition du marché
La forme la plus courante de cancer du sang, la leucémie myéloïde aiguë (LMA), est également l'une des formes rares de leucémie. Cette forme de cancer envahit le sang, qui se propage ensuite aux organes et systèmes corporels voisins. Les spécialistes doivent diagnostiquer manuellement les cellules cancéreuses et non cancéreuses en examinant les images cellulaires au microscope et en fournissant des étiquettes par annotation.
Rising healthcare expenditure can result in better provisions of R&D opportunities, which also propel business growth. The growing plethora of clinical research and diagnostic laboratories for the pre-testing of cancer is allowing the market to expand.
The increasing number of cancer cases and increasing awareness of leukemia have led to increased market growth.
The Europe acute myeloid leukemia diagnostics market is growing in the forecast year due to the rise in market players and the availability of advanced imaging instruments and consumables. Along with this, manufacturers are engaged in R&D activity for launching products in the market. The increasing R&D and pre-testing are further boosting the market growth. However, strict regulations and standards for the approval and commercialization of cancer diagnostic products and late diagnosis are expected to act as a challenge to market growth.
Europe Acute Myeloid Leukemia Diagnostics Market Dynamics
This section deals with understanding the market drivers, restraints, opportunities, and challenges. All of this is discussed in detail below:
DRIVERS
- Growing Prevalence of Leukemia Cancer
All ages can be affected by leukemia. Leukemia can be difficult to diagnose because, despite its wide range of signs and symptoms, it is non-specific and can be linked to other, more widespread medical conditions. AML is one of the four common types of leukemia in adults. It occurs less frequently. It is slightly more common among men than women, however, the average lifetime risk of getting AML in both sexes is about ½ of 1% on average.
AML is the second most common type of leukemia diagnosed in adults and children, but most cases occur in adults. Although it can be diagnosed at any age, it is uncommon before age 45. The average age of diagnosis is age 68. Rising maternal obesity rates may be partially responsible for the rise in the prevalence of AML.
Due to various risk factors, AML incidence has been rising, becoming a significant socio-economic issue. This is expected to act as a driver for market growth.
- Novel Technological Advancements in Leukemia Diagnostics
The most common form of blood cancer, AML, is also one of the uncommon forms of leukemia. This form of cancer invades in blood, which then spreads to nearby organs and bodily systems. Specialists must manually diagnose cancer and non-cancer cells by examining cell images under a microscope and providing labels through annotation. However, this hand microscopic examination is time-consuming and could give an incorrect diagnosis.
The risk of prescribing incorrect drugs was then reduced using computerized software. The creation of an automatic and reliable classification system became vital to stop the devastating effects of leukemia disease. Multiple segmentation techniques constituted the foundation of the existing leukemia classification algorithms.
The development of several new diagnostic methods will increase the market growth as many new and advanced products are launched. Hence, it is expected to create demand for acute leukemic cancer diagnostic products in the market.
RESTRAINTS
- Strict Regulations and Standards for the Approval and Commercialization of Leukemia Diagnostic Products
The stringent regulations for the commercialization of any product in the market are proving to be a big challenge for the manufacturers of cancer diagnostic products that have regulations and a different body for the regulatory procedures.
Manufacturers first have to check the CE mark approval for their product's commercialization into the market. The stringent regulatory policies are expected to hinder the growth and development of the market.
- Late Diagnosis and Poor Prognosis of Leukemia
Cancer is the leading cause of death in the world. However, if they are identified early on and given the right care, some cancers can be cured. The diagnostic process may experience delays in cancer diagnosis. When patients overlook or fail to respond to potential cancerous signs, the diagnosis gets delayed. The main cause of delayed presentation is the lack of public knowledge of early cancer signs, especially if such symptoms are unusual.
The late diagnosis often results from these factors, which result in poor prognosis. Thus, these are expected to restrain the market growth.
OPPORTUNITY/CHALLENGES
- Increased Cost, Safety, and Convenience Issues
Leukemia is fatal cancer, and the diagnosis process of leukemia also has safety issues. It is not cost-effective. One of the most costly medical disorders to treat is cancer. Cancer patients may be hospitalized and receive a variety of therapies, such as surgery, radiation therapy, and systemic therapy. Health insurance premiums for cancer patients are now more expensive than in the past. In addition, their copayment, deductible, and coinsurance costs are rising.
Henceforth, the current leukemia diagnosis process has safety, cost, and convenience issues, which are expected to act as a challenge to market growth.
Recent Developments
- In November 2022, Canon Inc. acquired Redlen Technologies Inc. (Redlen), one of the world's leading companies in creating new technologies related to the development and manufacture of semiconductor detector modules. Canon Medical Systems Corporation (Canon Medical), a group company of Canon Inc., has developed the first domestically produced Photon-Counting CT (PCCT) system incorporating Redlen's advanced technologies. This system has been installed at the National Cancer Center (NCC) Exploratory Oncology Research & Clinical Trial Center in Japan, where it is currently used to conduct research exploring the clinical applications of PCCT.
- In October 2022, Sysmex Corporation Chairman and its CEO: Hisashi Ietsugu announces the approval, of an application for a partial change to the manufacturing and marketing approval in Japan of its gene amplification reagent LYNOAMP CK19 marketed as a lymph node metastasis test reagent for breast cancer, colorectal cancer, gastric cancer, and non-small cell lung cancer, expanding its amplification to cervical cancer and endometrial cancer.
Europe Acute Myeloid Leukemia Diagnostics Market Scope
The Europe acute myeloid leukemia diagnostics market is segmented into seven notable segments based on product type, test type, cancer type, age group, gender, end user, and distribution channel. The growth amongst these segments will help you analyze major growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.
Product Type
- Instruments
- Consumables & Accessories
Based on product type, the market is segmented into instruments and consumables & accessories.
Test Type
- Blood Test
- Imaging Test
- Bone Marrow Test
- Genetic Testing
- Biomarker Test
- Immunophenotyping
- Others
Based on test type, the market is segmented into blood test, imaging test, bone marrow test, genetic testing, biomarker test, Immunophenotyping, and others.
Cancer Type
- Myeloblastic (M0)
- Myeloblastic (M1)
- Myeloblastic (M2)
- Promyelocytic (M3)
- Myelomonocytic (M4)
- Monocytic (M5)
- Erythroleukemia (M6)
- Megakaryocytic (M7)
Based on cancer type, the market is segmented into myeloblastic (M0), myeloblastic (M1), myeloblastic (M2), promyelocytic (M3), myelomonocytic (M4), monocytic (M5), erythroleukemia (M6), and megakaryocytic (M7).
Age Group
- Below 21
- 21-29
- 30-65
- 65 and Above
Based on age group, the market is segmented into below 21, 21-29, 30-65, and 65 and above.
Gender
- Male
- Female
Based on gender, the market is segmented into male and female.
End User
- Hospital
- Associated Labs
- Independent Diagnostic Laboratories
- Diagnostic Imaging Centers
- Cancer Research Institutes
- Others
Based on end user, the market is segmented into hospital, associated labs, independent diagnostic laboratories, diagnostic imaging centers, cancer research institutes, and others.
Distribution Channel
- Direct Tender
- Retail Sales
Based on distribution channel, the market is segmented into direct tender and retail sales.
Europe Acute Myeloid Leukemia Diagnostics Market Regional Analysis/Insights
The Europe acute myeloid leukemia diagnostics market is analyzed and market size insights and trends are provided by country based on product type, test type, cancer type, age group, gender, end user, and distribution channel.
The countries covered in this market report are Germany, U.K., France, Italy, Spain, Russia, Netherlands, Switzerland, Belgium, Turkey, and rest of Europe as referenced above.
L'Allemagne domine le marché européen du diagnostic de la leucémie myéloïde aiguë en termes de part de marché et de chiffre d'affaires et continuera de renforcer sa domination au cours de la période de prévision. Cela est dû aux avancées technologiques croissantes dans les instruments de diagnostic et les consommables dans la région, aux investissements croissants en R&D et au lancement de nouveaux produits qui stimulent la croissance du marché.
La section par pays du rapport fournit également des facteurs individuels ayant un impact sur le marché et des changements dans la réglementation du marché qui ont un impact sur les tendances actuelles et futures du marché. Des points de données, tels que les ventes de produits neufs et de remplacement, la démographie des pays, l'épidémiologie des maladies et les tarifs d'importation et d'exportation sont quelques-uns des principaux indicateurs utilisés pour prévoir le scénario du marché pour les différents pays. En outre, la présence et la disponibilité des marques européennes et les défis auxquels elles sont confrontées en raison de la concurrence des marques locales et nationales et l'impact des canaux de vente sont pris en compte tout en fournissant une analyse prévisionnelle des données nationales.
Analyse du paysage concurrentiel et des parts de marché du diagnostic de la leucémie myéloïde aiguë en Europe
Le paysage concurrentiel du marché européen du diagnostic de la leucémie myéloïde aiguë fournit des détails par concurrent. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements en R&D, les nouvelles initiatives du marché, la présence en Europe, les sites et installations de production, les capacités de production, les forces et les faiblesses de l'entreprise, le lancement du produit, la largeur et l'étendue du produit et la domination des applications. Les points de données ci-dessus fournis ne concernent que l'orientation des entreprises par rapport au marché.
Certains des principaux acteurs opérant sur le marché européen du diagnostic de la leucémie myéloïde aiguë sont Epigenomics AG, F. Hoffmann-La Roche Ltd, Siemens Healthcare GmbH, BIOMERIEUX, Merck KGaA, DiaSorin SpA, Koninklijke Philips NV, Sonic Healthcare et SternMed GmbH, entre autres.
SKU-
Accédez en ligne au rapport sur le premier cloud mondial de veille économique
- Tableau de bord d'analyse de données interactif
- Tableau de bord d'analyse d'entreprise pour les opportunités à fort potentiel de croissance
- Accès d'analyste de recherche pour la personnalisation et les requêtes
- Analyse de la concurrence avec tableau de bord interactif
- Dernières actualités, mises à jour et analyse des tendances
- Exploitez la puissance de l'analyse comparative pour un suivi complet de la concurrence
Table des matières
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET END USER COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER'S 5 FORCES
5 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, REGULATIONS
5.1 REGULATORY SCENARIO IN THE U.S.
5.2 REGULATORY SCENARIO IN AUSTRALIA
5.3 REGULATORY SCENARIO IN JAPAN
5.4 REGULATORY SCENARIO IN CHINA
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 GROWING PREVALENCE OF LEUKEMIA CANCER
6.1.2 NOVEL TECHNOLOGICAL ADVANCEMENTS IN LEUKEMIA DIAGNOSTICS
6.1.3 RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UPS
6.1.4 INCREASE IN AWARENESS REGARDING LEUKEMIA CANCER
6.2 RESTRAINTS
6.2.1 STRICT REGULATIONS AND STANDARDS FOR THE APPROVAL AND COMMERCIALIZATION OF LEUKEMIA DIAGNOSTIC PRODUCTS
6.2.2 LATE DIAGNOSIS AND POOR PROGNOSIS OF LEUKEMIA
6.3 OPPORTUNITIES
6.3.1 INCREASE IN DIAGNOSTIC PRODUCTS FOR LEUKEMIA
6.3.2 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS AND TREATMENT
6.3.3 GOVERNMENT INITIATIVES TOWARD CANCER DIAGNOSTICS
6.4 CHALLENGES
6.4.1 INCREASED COST, SAFETY, AND CONVENIENCE ISSUES
6.4.2 LACK OF SKILLED AND CERTIFIED PROFESSIONALS
7 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE
7.1 OVERVIEW
7.2 INSTRUMENTS
7.2.1 BIOPSY INSTRUMENTS
7.2.1.1 BONE MARROW BIOPSY
7.2.1.2 NEEDLE BIOPSY
7.2.1.3 SURGICAL BIOPSY
7.2.1.4 OTHERS
7.2.2 PATHOLOGY-BASED INSTRUMENTS
7.2.2.1 PCR INSTRUMENTS
7.2.2.2 SLIDE STAINING SYSTEMS
7.2.2.3 TISSUE PROCESSING SYSTEMS
7.2.2.4 CELL PROCESSORS
7.2.2.5 OTHER PATHOLOGY-BASED INSTRUMENTS
7.2.3 IMAGING INSTRUMENTS
7.2.3.1 ULTRASOUND SYSTEMS
7.2.3.2 CT SYSTEMS
7.2.3.3 MRI SYSTEMS
7.2.3.4 OTHERS
7.2.4 OTHERS
7.3 CONSUMABLES & ACCESSORIES
7.3.1 KITS
7.3.1.1 PCR KITS
7.3.1.2 DNA POLYMERASE KITS
7.3.1.3 NUCLEIC ACID ISOLATION KITS
7.3.1.4 OTHERS
7.3.2 REAGENTS
7.3.2.1 ASSAYS
7.3.2.2 BUFFERS
7.3.2.3 PRIMERS
7.3.2.4 OTHERS
7.3.3 PROBES
7.3.4 OTHER CONSUMABLES
8 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE
8.1 OVERVIEW
8.2 BLOOD TEST
8.2.1 COMPLETE BLOOD COUNT (CBC)
8.2.2 BLOOD CHEMISTRY TESTS
8.2.3 OTHERS
8.3 IMAGING TEST
8.3.1 COMPUTED TOMOGRAPHY (CT) SCAN
8.3.2 MRI
8.3.3 POSITRON EMISSION TOMOGRAPHY (PET) SCAN
8.3.4 OTHERS
8.4 BONE MARROW TESTS
8.4.1 BONE MARROW ASPIRATE
8.4.2 BONE MARROW BIOPSY
8.4.3 OTHERS
8.5 GENETIC TESTS
8.5.1 FLUORESCENCE IN SITU HYBRIDIZATION (FISH)
8.5.2 KARYOTYPING
8.5.3 OTHERS
8.6 BIOMARKER TEST
8.6.1 GENETIC ACUTE MYELOID LEUKEMIA (AML) BIOMARKER
8.6.2 EPIGENETIC ACUTE MYELOID LEUKEMIA (AML) BIOMARKER
8.6.3 PROTEOMIC ACUTE MYELOID LEUKEMIA (AML) BIOMARKER
8.7 IMMUNOPHENOTYPING
8.7.1 FLOW CYTOMETRY
8.7.2 IMMUNOHISTOCHEMISTRY
8.7.3 OTHERS
8.8 OTHERS
9 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE
9.1 OVERVIEW
9.2 MYELOBLASTIC (M0)
9.3 MYELOBLASTIC (M1)
9.4 MYELOBLASTIC (M2)
9.5 PROMYELOCYTIC (M3)
9.6 MYELOMONOCYTIC (M4)
9.7 MONOCYTIC (M5)
9.8 ERYTHROLEUKEMIA (M6)
9.9 MEGAKARYOCYTIC (M7)
10 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP
10.1 OVERVIEW
10.2 65 AND ABOVE
10.3 30-65
10.4 BELOW 21
10.5 21-29
11 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER
11.1 OVERVIEW
11.2 MALE
11.3 FEMALE
12 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER
12.1 OVERVIEW
12.2 HOSPITALS
12.3 ASSOCIATED LABS
12.4 INDEPENDENT DIAGNOSTIC LABORATORIES
12.5 DIAGNOSTIC IMAGING CENTERS
12.6 CANCER RESEARCH INSTITUTES
12.7 OTHERS
13 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL
13.1 OVERVIEW
13.2 DIRECT TENDER
13.3 RETAIL SALES
14 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION
14.1 EUROPE
14.1.1 GERMANY
14.1.2 UNITED KINGDOM
14.1.3 FRANCE
14.1.4 ITALY
14.1.5 SPAIN
14.1.6 RUSSIA
14.1.7 NETHERLANDS
14.1.8 SWITZERLAND
14.1.9 BELGIUM
14.1.10 TURKEY
14.1.11 REST OF EUROPE
15 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: COMPANY LANDSCAPE
15.1 COMPANY SHARE ANALYSIS: EUROPE
16 SWOT ANALYSIS
17 COMPANY PROFILE
17.1 CANON MEDICAL SYSTEMS CORPORATION.
17.1.1 COMPANY SNAPSHOT
17.1.2 REVENUE ANALYSIS
17.1.3 COMPANY SHARE ANALYSIS
17.1.4 PRODUCT PORTFOLIO
17.1.5 RECENT DEVELOPMENT
17.2 SYSMEX CORPORATION
17.2.1 COMPANY SNAPSHOT
17.2.2 REVENUE ANALYSIS
17.2.3 COMPANY SHARE ANALYSIS
17.2.4 PRODUCT PORTFOLIO
17.2.5 RECENT DEVELOPMENT
17.3 EPIGENOMICS AG.
17.3.1 COMPANY SNAPSHOT
17.3.2 REVENUE ANALYSIS
17.3.3 COMPANY SHARE ANALYSIS
17.3.4 PRODUCT PORTFOLIO
17.3.5 RECENT DEVELOPMENT
17.4 MYRIAD GENETICS, INC..
17.4.1 COMPANY SNAPSHOT
17.4.2 REVENUE ANALYSIS
17.4.3 COMPANY SHARE ANALYSIS
17.4.4 PRODUCT PORTFOLIO
17.4.5 RECENT DEVELOPMENT
17.5 F. HOFFMANN- LA ROCHE LTD
17.5.1 COMPANY SNAPSHOT
17.5.2 REVENUE ANALYSIS
17.5.3 COMPANY SHARE ANALYSIS
17.5.4 PRODUCT PORTFOLIO
17.5.5 RECENT DEVELOPMENT
17.6 ABBOTT
17.6.1 COMPANY SNAPSHOT
17.6.2 REVENUE ANALYSIS
17.6.3 PRODUCT PORTFOLIO
17.6.4 RECENT DEVELOPMENT
17.7 AGILENT TECHNOLOGIES, INC.
17.7.1 COMPANY SNAPSHOT
17.7.2 REVENUE ANALYSIS
17.7.3 PRODUCT PORTFOLIO
17.7.4 RECENT DEVELOPMENT
17.8 BD
17.8.1 COMPANY SNAPSHOT
17.8.2 REVENUE ANALYSIS
17.8.3 PRODUCT PORTFOLIO
17.8.4 RECENT DEVELOPMENT
17.9 BIOMERIEUX
17.9.1 COMPANY SNAPSHOT
17.9.2 PRODUCT PORTFOLIO
17.9.3 RECENT DEVELOPMENT
17.1 BIO-RAD LABORATORIES, INC.
17.10.1 COMPANY SNAPSHOT
17.10.2 REVENUE ANALYSIS
17.10.3 PRODUCT PORTFOLIO
17.10.4 RECENT DEVELOPMENT
17.11 DIASORIN S.P.A.
17.11.1 COMPANY SNAPSHOT
17.11.2 REVENUE ANALYSIS
17.11.3 PRODUCT PORTFOLIO
17.11.4 RECENT DEVELOPMENTS
17.12 EXACT SCIENCES CORPORATION
17.12.1 COMPANY SNAPSHOT
17.12.2 REVENUE ANALYSIS
17.12.3 PRODUCT PORTFOLIO
17.12.4 RECENT DEVELOPMENTS
17.13 FONAR CORP.
17.13.1 COMPANY SNAPSHOT
17.13.2 REVENUE ANALYSIS
17.13.3 PRODUCT PORTFOLIO
17.13.4 RECENT DEVELOPMENT
17.14 HOLOGIC INC.
17.14.1 COMPANY SNAPSHOT
17.14.2 REVENUE ANALYSIS
17.14.3 PRODUCT PORTFOLIO
17.14.4 RECENT DEVELOPMENT
17.15 ILLUMINA, INC.
17.15.1 COMPANY SNAPSHOT
17.15.2 REVENUE ANALYSIS
17.15.3 PRODUCT PORTFOLIO
17.15.4 RECENT DEVELOPMENT
17.16 KONINKLIJKE PHILIPS N.V.
17.16.1 COMPANY SNAPSHOT
17.16.2 REVENUE ANALYSIS
17.16.3 PRODUCT PORTFOLIO
17.16.4 RECENT DEVELOPMENT
17.17 MEDONICA CO. LTD
17.17.1 COMPANY SNAPSHOT
17.17.2 PRODUCT PORTFOLIO
17.17.3 RECENT DEVELOPMENT
17.18 MERCK KGAA
17.18.1 COMPANY SNAPSHOT
17.18.2 REVENUE ANALYSIS
17.18.3 PRODUCT PORTFOLIO
17.18.4 RECENT DEVELOPMENTS
17.19 MINFOUND MEDICAL SYSTEMS CO., LTD
17.19.1 COMPANY SNAPSHOT
17.19.2 PRODUCT PORTFOLIO
17.19.3 RECENT DEVELOPMENT
17.2 PLEXBIO
17.20.1 COMPANY SNAPSHOT
17.20.2 PRODUCT PORTFOLIO
17.20.3 RECENT DEVELOPMENTS
17.21 QIAGEN
17.21.1 COMPANY SNAPSHOT
17.21.2 REVENUE ANALYSIS
17.21.3 PRODUCT PORTFOLIO
17.21.4 RECENT DEVELOPMENTS
17.22 QUEST DIAGNOSTICS INCORPORATED
17.22.1 COMPANY SNAPSHOT
17.22.2 REVENUE ANALYSIS
17.22.3 PRODUCT PORTFOLIO
17.22.4 RECENT DEVELOPMENTS
17.23 SIEMENS HEALTHCARE GMBH
17.23.1 COMPANY SNAPSHOT
17.23.2 REVENUE ANALYSIS
17.23.3 PRODUCT PORTFOLIO
17.23.4 RECENT DEVELOPMENT
17.24 SONIC HEALTHCARE
17.24.1 COMPANY SNAPSHOT
17.24.2 PRODUCT PORTFOLIO
17.24.3 RECENT DEVELOPMENT
17.25 STERNMED GMBH
17.25.1 COMPANY SNAPSHOT
17.25.2 PRODUCT PORTFOLIO
17.25.3 RECENT DEVELOPMENTS
17.26 THERMO FISHER SCIENTIFIC INC.
17.26.1 COMPANY SNAPSHOT
17.26.2 REVENUE ANALYSIS
17.26.3 PRODUCT PORTFOLIO
17.26.4 RECENT DEVELOPMENT
17.27 TIME MEDICAL HOLDING
17.27.1 COMPANY SNAPSHOT
17.27.2 PRODUCT PORTFOLIO
17.27.3 RECENT DEVELOPMENT
18 QUESTIONNAIRE
19 RELATED REPORTS
Liste des tableaux
TABLE 1 APPROVED DIAGNOSTICS OF LEUKEMIA
TABLE 2 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 3 EUROPE INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 4 EUROPE INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 5 EUROPE BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 6 EUROPE PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 7 EUROPE IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 8 EUROPE CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 9 EUROPE CONSUMABLES AND ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 10 EUROPE KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 11 EUROPE REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 12 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 13 EUROPE BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 14 EUROPE BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 15 EUROPE IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 16 EUROPE IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 17 EUROPE BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 18 EUROPE BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 19 EUROPE GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 20 EUROPE GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 21 EUROPE BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 22 EUROPE BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 23 EUROPE IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 24 EUROPE IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 25 EUROPE OTHERS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 26 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 27 EUROPE MYELOBLASTIC (M0) IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 28 EUROPE MYELOBLASTIC (M1) IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 29 EUROPE MYELOBLASTIC (M2) IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 30 EUROPE PROMYELOCYTIC (M3) IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 31 EUROPE MYELOMONOCYTIC (M4) IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 32 EUROPE MONOCYTIC (M5) IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 33 EUROPE ERYTHROLEUKEMIA (M6) IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 34 EUROPE MEGAKARYOCYTIC (M7) ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 35 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 36 EUROPE 65 AND ABOVE IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 37 EUROPE 30-65 IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 38 EUROPE BELOW 21 IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 39 EUROPE 21-29 IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 40 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 41 EUROPE MALE IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 42 EUROPE FEMALE IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 43 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 44 EUROPE HOSPITALS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 45 EUROPE ASSOCIATED LABS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 46 EUROPE INDEPENDENT DIAGNOSTIC LABORATORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 47 EUROPE DIAGNOSTIC IMAGING CENTERS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 48 EUROPE CANCER RESEARCH INSTITUTES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 49 EUROPE OTHERS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 50 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 51 EUROPE DIRECT TENDER IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 52 EUROPE RETAIL SALES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 53 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 54 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 55 EUROPE INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 56 EUROPE PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 57 EUROPE IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 58 EUROPE BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 59 EUROPE CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 60 EUROPE KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 61 EUROPE REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 62 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 63 EUROPE IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 64 EUROPE BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 65 EUROPE BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 66 EUROPE BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 67 EUROPE IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 68 EUROPE GENETIC TESTING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 69 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 70 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 71 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 72 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 73 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 74 GERMANY ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 75 GERMANY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 76 GERMANY PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 77 GERMANY IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 78 GERMANY BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 79 GERMANY CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 80 GERMANY KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 81 GERMANY REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 82 GERMANY ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 83 GERMANY IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 84 GERMANY BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 85 GERMANY BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 86 GERMANY BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 87 GERMANY IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 88 GERMANY GENETIC TESTING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 89 GERMANY ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 90 GERMANY ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 91 GERMANY ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 92 GERMANY ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 93 GERMANY ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 94 UNITED KINGDOM ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 95 UNITED KINGDOM INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 96 UNITED KINGDOM PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 97 UNITED KINGDOM IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 98 UNITED KINGDOM BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 99 UNITED KINGDOM CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 100 UNITED KINGDOM KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 101 UNITED KINGDOM REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 102 UNITED KINGDOM ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 103 UNITED KINGDOM IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 104 UNITED KINGDOM BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 105 UNITED KINGDOM BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 106 UNITED KINGDOM BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 107 UNITED KINGDOM IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 108 UNITED KINGDOM IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 109 UNITED KINGDOM ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 110 UNITED KINGDOM ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 111 UNITED KINGDOM ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 112 UNITED KINGDOM ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 113 UNITED KINGDOM ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 114 FRANCE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 115 FRANCE INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 116 FRANCE PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 117 FRANCE IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 118 FRANCE BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 119 FRANCE CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 120 FRANCE KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 121 FRANCE REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 122 FRANCE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 123 FRANCE IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 124 FRANCE BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 125 FRANCE BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 126 FRANCE BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 127 FRANCE IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 128 FRANCE GENETIC TESTING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 129 FRANCE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 130 FRANCE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 131 FRANCE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 132 FRANCE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 133 FRANCE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 134 ITALY ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 135 ITALY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 136 ITALY PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 137 ITALY IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 138 ITALY BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 139 ITALY CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 140 ITALY KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 141 ITALY REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 142 ITALY ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 143 ITALY IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 144 ITALY BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 145 ITALY BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 146 ITALY BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 147 ITALY IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 148 ITALY GENETIC TESTING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 149 ITALY ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 150 ITALY ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 151 ITALY ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 152 ITALY ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 153 ITALY ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 154 SPAIN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 155 SPAIN INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 156 SPAIN PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 157 SPAIN IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 158 SPAIN BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 159 SPAIN CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 160 SPAIN KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 161 SPAIN REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 162 SPAIN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 163 SPAIN IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 164 SPAIN BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 165 SPAIN BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 166 SPAIN BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 167 SPAIN IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 168 SPAIN GENETIC TESTING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 169 SPAIN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 170 SPAIN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 171 SPAIN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 172 SPAIN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 173 SPAIN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 174 RUSSIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 175 RUSSIA INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 176 RUSSIA PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 177 RUSSIA IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 178 RUSSIA BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 179 RUSSIA CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 180 RUSSIA KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 181 RUSSIA REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 182 RUSSIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 183 RUSSIA IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 184 RUSSIA BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 185 RUSSIA BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 186 RUSSIA BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 187 RUSSIA IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 188 RUSSIA GENETIC TESTING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 189 RUSSIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 190 RUSSIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 191 RUSSIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 192 RUSSIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 193 RUSSIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 194 NETHERLANDS ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 195 NETHERLANDS INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 196 NETHERLANDS PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 197 NETHERLANDS IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 198 NETHERLANDS BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 199 NETHERLANDS CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 200 NETHERLANDS KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 201 NETHERLANDS REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 202 NETHERLANDS ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 203 NETHERLANDS IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 204 NETHERLANDS BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 205 NETHERLANDS BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 206 NETHERLANDS BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 207 NETHERLANDS IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 208 NETHERLANDS GENETIC TESTING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 209 NETHERLANDS ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 210 NETHERLANDS ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 211 NETHERLANDS ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 212 NETHERLANDS ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 213 NETHERLANDS ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 214 NETHERLANDS ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 215 SWITZERLAND ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 216 SWITZERLAND INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 217 SWITZERLAND PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 218 SWITZERLAND IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 219 SWITZERLAND BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 220 SWITZERLAND CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 221 SWITZERLAND KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 222 SWITZERLAND REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 223 SWITZERLAND ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 224 SWITZERLAND IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 225 SWITZERLAND BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 226 SWITZERLAND BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 227 SWITZERLAND BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 228 SWITZERLAND IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 229 SWITZERLAND GENETIC TESTING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 230 SWITZERLAND ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 231 SWITZERLAND ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 232 SWITZERLAND ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 233 SWITZERLAND ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 234 SWITZERLAND ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 235 BELGIUM ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 236 BELGIUM INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 237 BELGIUM PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 238 BELGIUM IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 239 BELGIUM BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 240 BELGIUM CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 241 BELGIUM KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 242 BELGIUM REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 243 BELGIUM ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 244 BELGIUM IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 245 BELGIUM BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 246 BELGIUM BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 247 BELGIUM BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 248 BELGIUM IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 249 BELGIUM GENETIC TESTING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 250 BELGIUM ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 251 BELGIUM ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 252 BELGIUM ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 253 BELGIUM ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 254 BELGIUM ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 255 TURKEY ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 256 TURKEY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 257 TURKEY PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 258 TURKEY IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 259 TURKEY BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 260 TURKEY CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 261 TURKEY KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 262 TURKEY REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 263 TURKEY ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 264 TURKEY IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 265 TURKEY BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 266 TURKEY BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 267 TURKEY BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 268 TURKEY IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 269 TURKEY GENETIC TESTING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 270 TURKEY ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 271 TURKEY ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 272 TURKEY ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 273 TURKEY ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 274 TURKEY ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 275 REST OF EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
Liste des figures
FIGURE 1 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET : SEGMENTATION
FIGURE 2 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET : DATA TRIANGULATION
FIGURE 3 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET : DROC ANALYSIS
FIGURE 4 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET : EUROPE VS REGIONAL MARKET ANALYSIS
FIGURE 5 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET : COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET : INTERVIEW DEMOGRAPHICS
FIGURE 7 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET : DBMR MARKET POSITION GRID
FIGURE 8 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET : MARKET END USER COVERAGE GRID
FIGURE 9 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET : VENDOR SHARE ANALYSIS
FIGURE 10 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET : SEGMENTATION
FIGURE 11 THE GROWING PREVALENCE OF LEUKEMIA CANCER IS EXPECTED TO DRIVE THE EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET IN THE FORECAST PERIOD
FIGURE 12 THE INSTRUMENTS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET IN 2023 & 2030
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET
FIGURE 14 NUMBER OF PREVALENCE OF LEUKEMIA INCIDENCE WORLDWIDE (BOTH SEXES)
FIGURE 15 FIVE YEARS PREVALENCE LEUKEMIA INCIDENCE WORLDWIDE (BOTH SEXES)
FIGURE 16 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2022
FIGURE 17 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2023-2030 (USD MILLION)
FIGURE 18 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY PRODUCT TYPE, CAGR (2023-2030)
FIGURE 19 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY PRODUCT TYPE, LIFELINE CURVE
FIGURE 20 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY TEST TYPE, 2022
FIGURE 21 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY TEST TYPE, 2023-2030 (USD MILLION)
FIGURE 22 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY TEST TYPE, CAGR (2023-2030)
FIGURE 23 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY TEST TYPE, LIFELINE CURVE
FIGURE 24 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY CANCER TYPE, 2022
FIGURE 25 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY CANCER TYPE, 2023-2030 (USD MILLION)
FIGURE 26 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY CANCER TYPE, CAGR (2023-2030)
FIGURE 27 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY CANCER TYPE, LIFELINE CURVE
FIGURE 28 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY AGE GROUP, 2022
FIGURE 29 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY AGE GROUP, 2023-2030 (USD MILLION)
FIGURE 30 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY AGE GROUP, CAGR (2023-2030)
FIGURE 31 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY AGE GROUP, LIFELINE CURVE
FIGURE 32 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY GENDER, 2022
FIGURE 33 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY GENDER, 2023-2030 (USD MILLION)
FIGURE 34 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY GENDER, CAGR (2023-2030)
FIGURE 35 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY GENDER, LIFELINE CURVE
FIGURE 36 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY END USER, 2022
FIGURE 37 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY END USER, 2023-2030 (USD MILLION)
FIGURE 38 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY END USER, CAGR (2023-2030)
FIGURE 39 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY END USER, LIFELINE CURVE
FIGURE 40 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2022
FIGURE 41 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)
FIGURE 42 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 43 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 44 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: SNAPSHOT (2022)
FIGURE 45 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY COUNTRY (2022)
FIGURE 46 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030)
FIGURE 47 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030)
FIGURE 48 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: PRODUCT TYPE (2023-2030)
FIGURE 49 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%)
Méthodologie de recherche
La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. L'étape consiste à obtenir des informations sur le marché ou des données connexes via diverses sources et stratégies. Elle comprend l'examen et la planification à l'avance de toutes les données acquises dans le passé. Elle englobe également l'examen des incohérences d'informations observées dans différentes sources d'informations. Les données de marché sont analysées et estimées à l'aide de modèles statistiques et cohérents de marché. De plus, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. Pour en savoir plus, veuillez demander un appel d'analyste ou déposer votre demande.
La méthodologie de recherche clé utilisée par l'équipe de recherche DBMR est la triangulation des données qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). Les modèles de données incluent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement des entreprises, l'analyse des brevets, l'analyse des prix, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse globale par rapport à l'analyse régionale et des parts des fournisseurs. Pour en savoir plus sur la méthodologie de recherche, envoyez une demande pour parler à nos experts du secteur.
Personnalisation disponible
Data Bridge Market Research est un leader de la recherche formative avancée. Nous sommes fiers de fournir à nos clients existants et nouveaux des données et des analyses qui correspondent à leurs objectifs. Le rapport peut être personnalisé pour inclure une analyse des tendances des prix des marques cibles, une compréhension du marché pour d'autres pays (demandez la liste des pays), des données sur les résultats des essais cliniques, une revue de la littérature, une analyse du marché des produits remis à neuf et de la base de produits. L'analyse du marché des concurrents cibles peut être analysée à partir d'une analyse basée sur la technologie jusqu'à des stratégies de portefeuille de marché. Nous pouvons ajouter autant de concurrents que vous le souhaitez, dans le format et le style de données que vous recherchez. Notre équipe d'analystes peut également vous fournir des données sous forme de fichiers Excel bruts, de tableaux croisés dynamiques (Fact book) ou peut vous aider à créer des présentations à partir des ensembles de données disponibles dans le rapport.
